SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001549595-24-000048
Filing Date
2024-04-10
Accepted
2024-04-10 07:02:02
Documents
14
Period of Report
2024-04-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K nrix-20240410.htm   iXBRL 8-K 27849
2 EX-99.1 nrix-20240410xexx991.htm EX-99.1 77771
  Complete submission text file 0001549595-24-000048.txt   251868

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nrix-20240410.xsd EX-101.SCH 1901
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT nrix-20240410_lab.xml EX-101.LAB 24350
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nrix-20240410_pre.xml EX-101.PRE 14116
17 EXTRACTED XBRL INSTANCE DOCUMENT nrix-20240410_htm.xml XML 3016
Mailing Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 (415) 660-5320
Nurix Therapeutics, Inc. (Filer) CIK: 0001549595 (see all company filings)

IRS No.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
Type: 8-K | Act: 34 | File No.: 001-39398 | Film No.: 24834228
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)